Thursday's vote by an FDA advisory committee to approve flibanserin for low sexual desire in pre-menopausal women has drawn sharp criticism for potential influence by a strong public relations campaign funded partly by pharmaceutical companies that include the drug's sponsor.
Source Forbes - Business http://ift.tt/1JAGIIw
ليست هناك تعليقات:
إرسال تعليق